Group 1 - The core business revenue composition of Zhongyuan Qihua for the year 2024 is as follows: manufacturing accounts for 70.04%, services account for 27.21%, and other businesses account for 2.76% [1] - Zhongyuan Qihua announced on July 29 that it plans to acquire a 25% stake in Shanghai Zhongyuan Jisheng Cell Technology Co., Ltd. from Shanghai Yanlin Biotechnology Co., Ltd. to enhance operational decision-making efficiency and increase investment in adult health cell storage business [3] - The total assessed value of 100% equity of Shanghai Zhongyuan Jisheng is approximately 15.2783 million yuan, with the agreed transaction price for the 25% stake being around 3.82 million yuan [3]

智通财经APP讯，中源协和(600645.SH)发布公告，为提高经营决策效率，继续加大对成人健康细胞存 储业务的资源投入，公司拟以自有资金收购上海延藜生物技术有限公司(以下简称"上海延藜公司")持有 的上海中源济生细胞科技有限公司(以下简称"上海中源济生公司")25%股权。本次交易转让价格为人民 币381.96万元。 本次交易完成后，上海中源济生公司成为公司全资子公司，在提高经营决策效率的同时，充分利用上海 中源济生公司前期已经投入使用的细胞生命体验馆等软硬件设施、初具规模的团队以及市场渠道，加快 整合公司各业务板块协同效率，为成人健康细胞存储业务在华东地区的发展构建完整业务闭环。 ...